Grifols A : Q2 2021 results in line with bioscience returning to positive organic growth and margins stabilising
>Grifols this morning published its Q2 2021 results which were in line with our expectations: bioscience returns to positive organic growth - Group sales decreased -2% to € 1.35bn (vs -8% posted in Q1 2021) with organic growth excl. forex of +5% vs.-1% in Q1 2021, in line with our estimates and beating the consensus by 4%. By division: we highlight the bioscience business posting sales decreasing -3% or +5% excl. forex (vs -13% posited in Q1 2021 or -6% ex forex), in ...Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.